ASX healthcare stock EBR Systems Inc (ASX: EBR) is under the spotlight today after a new announcement sent the stock price surging on Thursday.
EBR is a clinical stage company that has developed its patented Wireless Stimulation Endocardially (WiSE) technology for the treatment of cardiac rhythm disease and to eliminate the need for cardiac pacing leads when delivering cardiac resynchronisation therapy.
The healthcare stock rose roughly 7% yesterday after the company released an announcement to the ASX.
Image source: Getty Images
What did EBR systems announce?
Yesterday, the ASX healthcare stock released a preliminary version of its operating metrics earlier than scheduled by its quarterly reporting time frame (mid-May).
According to Bell Potter, it is no surprise EBR has provided an early release as it gears up toward an eventual and large capital raising.
In yesterday's report, the company said it saw strong Q1 2026 growth in commercial cases.
It reported:
- Robust commercial momentum continued through Q1 2026 with case volumes more than doubling from Q4 2025
- The WiSE® System was successfully implanted in 41 commercial patients during the quarter, bringing total
- implants across the pilot phase and Limited Market Release to 71
- EBR expects to report revenue in the range of US$2.25M to US$2.36M for Q1 2026, based on preliminary unaudited quarter-end results and subject to quarter-end closing adjustments.
John McCutcheon, EBR Systems' President & Chief Executive Officer said:
In Q1 2026, we made impressive progress across both our commercial and clinical programs. Case volumes increased strongly during the quarter, reflecting growing physician experience, expanding site readiness and the steady execution of our Limited Market Release. We also continued to advance important clinical initiatives, with further enrolment in both the WiSE-UP post-approval study and the TLC-AU feasibility study, helping to expand the body of evidence supporting the WiSE System across a broader patient population. We are encouraged by the momentum we are seeing and remain focused on disciplined execution, physician training, site activation and building the clinical and commercial foundation for broader adoption of the WiSE System.
What did Bell Potter have to say?
Following the release, the team at Bell Potter released updated guidance on the ASX healthcare stock.
The broker said the data continues to impress, with implants more than doubling to quarter of quarter to 41.
The success in implant volume is supported by the growing breadth of physicians trained and hospital contracts signed. A further 22 Physicians trained on the WiSE pacing system and 16 hospital contracts signed in the quarter, bringing the cumulative totals to 55 & 37. EBR appear be tracking well toward our hospital target of 60 for FY26.
Big upside for this ASX healthcare stock
Bell Potter has maintained its buy recommendation for EBR Systems, along with a price target of $2.00.
From yesterday's closing price of $0.68, that indicates a potential upside of 194%.
It is not surprising that the market has reacted well to the data release, and with each data release we grow more confident in EBR's commercial prospects and expect the market to do so as well.
